TY - JOUR
T1 - Effect of 6,7-dimethoxy-2,2-dimethyl-2h-chromene (Agerarin) on the recovery of filaggrin expression through targeting of janus kinases in the inflammatory skin
AU - Ahn, Sung Shin
AU - Lee, Young Han
AU - Yeo, Hyunjin
AU - Lee, Youngshim
AU - Min, Do Sik
AU - Lim, Yoongho
AU - Shin, Soon Young
N1 - Publisher Copyright:
© 2020, Taiwan Food and Drug Administration. All rights reserved.
PY - 2020
Y1 - 2020
N2 - Filaggrin (FLG) is a structural component of the stratum corneum that is essential for maintaining the barrier function of the skin and for the formation of natural moisturizing factors. 6,7-Dimethoxy-2,2-dimethyl-2H-chromene (Agerarin) is a bioactive compound derived from Ageratum houstonianum, a plant that is used as a traditional medicine to treat skin diseases. This study aimed to evaluate the effect of agerarin on skin inflammation in a dinitrochlorobenzene (DNCB)-induced atopic dermatitis mouse model. We found that the topical administration of agerarin ameliorates atopic dermatitis-like skin lesions. We also showed that agerarin restores the reduced filaggrin (FLG) expression in DNCB-applied skin sections. Moreover, agerarin decreased phosphorylation of JAK1 and JAK2 kinases to enhance FLG expression, which was reduced by TNFα+IFNγ and IL4+IL13 treatment, in HaCaT keratinocytes. These results demonstrate the feasibility of agerarin as a possible therapeutic against conditions of skin inflammation, such as atopic dermatitis, by improving the upregulation of FLG expression.
AB - Filaggrin (FLG) is a structural component of the stratum corneum that is essential for maintaining the barrier function of the skin and for the formation of natural moisturizing factors. 6,7-Dimethoxy-2,2-dimethyl-2H-chromene (Agerarin) is a bioactive compound derived from Ageratum houstonianum, a plant that is used as a traditional medicine to treat skin diseases. This study aimed to evaluate the effect of agerarin on skin inflammation in a dinitrochlorobenzene (DNCB)-induced atopic dermatitis mouse model. We found that the topical administration of agerarin ameliorates atopic dermatitis-like skin lesions. We also showed that agerarin restores the reduced filaggrin (FLG) expression in DNCB-applied skin sections. Moreover, agerarin decreased phosphorylation of JAK1 and JAK2 kinases to enhance FLG expression, which was reduced by TNFα+IFNγ and IL4+IL13 treatment, in HaCaT keratinocytes. These results demonstrate the feasibility of agerarin as a possible therapeutic against conditions of skin inflammation, such as atopic dermatitis, by improving the upregulation of FLG expression.
UR - http://www.scopus.com/inward/record.url?scp=85096963930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096963930&partnerID=8YFLogxK
U2 - 10.38212/2224-6614.1178
DO - 10.38212/2224-6614.1178
M3 - Article
AN - SCOPUS:85096963930
SN - 1021-9498
VL - 28
SP - 449
EP - 460
JO - Journal of Food and Drug Analysis
JF - Journal of Food and Drug Analysis
IS - 3
M1 - 6
ER -